NasdaqGS - Nasdaq Real Time Price USD

QuidelOrtho Corporation (QDEL)

39.12 +0.86 (+2.25%)
At close: 4:00 PM EDT
39.98 +0.86 (+2.20%)
After hours: 4:49 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Michael S. Iskra Interim CEO, Executive VP & Chief Commercial Officer 870.93k -- 1970
Mr. Robert J. Bujarski J.D. Interim President, Executive VP & COO 961.26k -- 1969
Mr. Joseph M. Busky CPA Chief Financial Officer 890.63k -- 1968
Dr. Werner Kroll Ph.D. Senior Vice President of Research & Development 1.03M -- 1957
Ms. Louise M. Brandy Chief Information Officer -- -- 1959
Ruben Argueta Director of Investor Relations -- -- --
Ms. Michelle A. Hodges J.D. Senior VP, General Counsel & Corporate Secretary 1.8M -- 1963
Mr. William J. Ferenczy Point of Care Business Unit Leader -- -- 1956
Ms. Tamara A. Ranalli Molecular Diagnostics Business Unit Leader -- -- 1973

QuidelOrtho Corporation

9975 Summers Ridge Road
San Diego, CA 92121
United States
858 552 1100 https://www.quidelortho.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
7,100

Description

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Corporate Governance

QuidelOrtho Corporation’s ISS Governance QualityScore as of April 1, 2024 is 3. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 4; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024
QuidelOrtho Corporation Earnings Call

Related Tickers

CNMD CONMED Corporation
72.64
+2.19%
 
NARI Inari Medical, Inc.
38.59
-0.13%
 
PODD Insulet Corporation
166.25
+0.92%
 
IART Integra LifeSciences Holdings Corporation
28.68
-9.33%
 
BIO Bio-Rad Laboratories, Inc.
279.73
-0.46%
 
IRTC iRhythm Technologies, Inc.
112.09
-0.03%
 
INSP Inspire Medical Systems, Inc.
229.22
-4.95%
 
MOTS Motus GI Holdings, Inc.
0.0758
+8.29%
 
NVCR NovoCure Limited
12.09
+0.33%
 
PACB Pacific Biosciences of California, Inc.
1.5500
+6.16%